efalizumab, Raptiva (cont.)
PRESCRIBED FOR: Efalizumab is used for the treatment of patients at least 18 years of age with chronic, moderate to severe plaque psoriasis.
DOSING: Efalizumab is given as weekly subcutaneous (beneath the skin) injections. The first dose is 0.7 mg per kilogram of body weight (1 kilogram equals 2.2 pounds). Thereafter, each weekly dose is 1 mg per kilogram (up to a maximum single dose of 200 mg).
Efalizumab should be administered using the disposable syringe and needles provided in the kit. The cap on the pre-filled syringe containing sterile water should be removed. Thereafter, the needle is attached to the syringe. Remove the plastic cap protecting the rubber stopper of the efalizumab vial and wipe the top of the rubber stopper with one of the provided alcohol swabs. After cleaning with the alcohol swab, do not touch the top of the vial. To prepare the efalizumab solution, slowly inject the 1.3 mL of sterile water in the provided pre-filled syringe into the efalizumab vial. Swirl the vial with a gentle circular motion to dissolve the product. Do not shake. This procedure should be done immediately before each use, and the solution that is made should be used only once. If it is not used immediately after it is made, store at room temperature and use within 8 hours. Following administration, discard any unused reconstituted efalizumab solution. Potential sites for injection include the thigh, abdomen, buttocks, or upper arm. Injection sites should be rotated.
DRUG INTERACTIONS: The safety and efficacy of efalizumab in combination with other immune-suppressing medicines have not been evaluated. It is recommended that patients receiving other immune-suppressing medicines should not receive efalizumab because of the possibility of increasing the risks of infections and tumors. The safety and efficacy of vaccines administered to patients being treated with efalizumab also have not been studied. Some vaccines consisting of live viruses which have been rendered inactive (attenuated) should not be used in patients taking efalizumab
PREGNANCY: Reproduction studies in animals have not been conducted with efalizumab. It also is not known whether efalizumab can cause harm to the fetus in humans. Therefore, efalizumab should be given to a pregnant woman only if the physician feels that its benefits clearly warrant the theoretical risks and with the patient's consent. Female patients also should notify their physicians if they become pregnant while taking efalizumab (or within 6 weeks of discontinuing efalizumab) and be encouraged to enroll in the RAPTIVA Pregnancy Registry.
NURSING MOTHERS: It is not known whether efalizumab passes into breast milk. Since animal data suggest a potential for side effects in nursing infants from similar (but not commercially available) drugs, a decision must be carefully made whether to discontinue nursing while taking efalizumab or to discontinue efalizumab, taking into account the importance of the drug to the mother.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index
- Allergic Skin Disorders
- Bacterial Skin Diseases
- Bites and Infestations
- Diseases of Pigment
- Fungal Skin Diseases
- Medical Anatomy and Illustrations
- Noncancerous, Precancerous & Cancerous Tumors
- Oral Health Conditions
- Papules, Scales, Plaques and Eruptions
- Scalp, Hair and Nails
- Sexually Transmitted Diseases (STDs)
- Vascular, Lymphatic and Systemic Conditions
- Viral Skin Diseases
- Additional Skin Conditions